Drug intelligence / Profile preview

KIO-201

Development stage: Phase 2
Lead developer: Kiora Pharmaceuticals
Modality: Recombinant Proteins and Enzymes, Hydrogel Systems → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Ophthalmic, Topical

Overview

KIO-201 is a chemically modified and cross-linked form of hyaluronic acid developed as a topical ophthalmic therapy to accelerate corneal wound healing. It is designed to provide enhanced shear-thinning properties and increased ocular surface residence time compared to standard hyaluronic acid formulations. KIO-201 acts as a protectant and facilitates re-epithelization of the corneal surface after injury or surgery by forming a thin coating over the eye. The drug is being developed primarily for persistent corneal epithelial defects (PCEDs) and other corneal injuries that are difficult to treat with current therapies[1][2][5][7]. Its mechanism of action involves replacing or supplementing endogenous hyaluronic acid on the ocular surface, thereby supporting tissue homeostasis and wound healing processes[2][5].

Brand names: RemendOcunovis ProCare BioHAnce
Other names: crosslinked thiolated carboxymethyl hyaluronic acid 0.75%

Targets

ICAM1 (Intercellular Adhesion Molecule 1)RHAMM (Hyaluronan-mediated motility receptor)CD44 (CD44 antigen)

Beyond the preview

Go deeper on KIO-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KIO-201.

Explore the full profile